Media headlines about Infinity Pharmaceuticals (NASDAQ:INFI) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 44.2862637334267 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
A number of research firms have recently issued reports on INFI. ValuEngine cut shares of Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Wells Fargo & Co raised shares of Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Thursday, October 12th. Finally, Zacks Investment Research raised shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th.
Infinity Pharmaceuticals (NASDAQ:INFI) opened at $2.05 on Friday. The stock has a market cap of $103.96, a PE ratio of -1.78 and a beta of 2.82. Infinity Pharmaceuticals has a 1 year low of $0.93 and a 1 year high of $3.84.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.06. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $14.70 million. During the same period last year, the company earned ($0.39) EPS. equities analysts anticipate that Infinity Pharmaceuticals will post -0.93 earnings per share for the current year.
In related news, President Lawrence E. Bloch acquired 500,000 shares of the business’s stock in a transaction dated Wednesday, December 6th. The shares were bought at an average price of $1.81 per share, with a total value of $905,000.00. Following the transaction, the president now directly owns 580,944 shares of the company’s stock, valued at $1,051,508.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 6.81% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/14/infinity-pharmaceuticals-infi-getting-somewhat-favorable-media-coverage-report-shows.html.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.